NCT01239992

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Ludwig-Maximilians - University of Munich · Academic / Other
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.

Conditions

• Hyperlipoproteinemia
• Metabolic Syndrome

Interventions

Type	Name	Description
DRUG	Niacin/ Laropiprant	1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-01-01
• Completion: 2013-07-01
• First posted: 2010-11-15
• Last updated: 2014-04-10
• Results posted: 2014-04-10

Locations

1 site across 1 country: Germany